Journal of the American Academy of Dermatology · 2019
Skin-directed radiation therapy for cutaneous lymphoma: The Mayo Clinic experience.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
King Brian J, Lester Scott C, Tolkachjov Stanislav N, Davis Mark D P, Gibson Lawrence E, Martenson James A
Аннотация
BACKGROUND: Focal or total skin radiation therapy can be used to treat mild to refractory cutaneous T-cell lymphoma.
OBJECTIVE: To report the broad therapeutic benefit of radiation therapy for cutaneous T-cell lymphoma.
METHODS: Retrospective, single-institution review of outcomes for skin-directed radiation therapy.
RESULTS: Skin-directed radiation therapy showed a 99% response rate and 80% complete response rate after treatment regardless of involvement, severity, histopathologic subtype, dose, or fractionation. The overall in-field recurrence rate was 15%, and median time to recurrence was 296 days (range, 1-1884 days). Focal and hypofractionated regimens were similarly associated with disease response and rare toxicity. Short-term rates of secondary skin cancer after treatment were comparable to expected incidence in a patient population without radiation.
LIMITATIONS: Large total number of treatments courses compared with overall number of patients. Heterogenous mix of treatment regimens (no standardization of dose or fraction number).
CONCLUSIONS: Radiation therapy is a well-tolerated treatment option for properly selected patients with cutaneous T-cell lymphoma.
OBJECTIVE: To report the broad therapeutic benefit of radiation therapy for cutaneous T-cell lymphoma.
METHODS: Retrospective, single-institution review of outcomes for skin-directed radiation therapy.
RESULTS: Skin-directed radiation therapy showed a 99% response rate and 80% complete response rate after treatment regardless of involvement, severity, histopathologic subtype, dose, or fractionation. The overall in-field recurrence rate was 15%, and median time to recurrence was 296 days (range, 1-1884 days). Focal and hypofractionated regimens were similarly associated with disease response and rare toxicity. Short-term rates of secondary skin cancer after treatment were comparable to expected incidence in a patient population without radiation.
LIMITATIONS: Large total number of treatments courses compared with overall number of patients. Heterogenous mix of treatment regimens (no standardization of dose or fraction number).
CONCLUSIONS: Radiation therapy is a well-tolerated treatment option for properly selected patients with cutaneous T-cell lymphoma.